



Cara Therapeutics
Investor Relations Department
107 Elm St. 9th Flr
Stamford, CT 06902
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: CARA

Last Trade:	13.95
Trade Time:	4:00 PM ET Aug 16, 2017
Change:	-0.11 ↓ (-0.782%)
Day Range	13.92 - 14.50
52-Week Range	5.27 - 28.50
Volume	647,263

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors.

We are developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics. Our most advanced product candidate, intravenous, or I.V... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 3, 2017*
[Cara Therapeutics Reports Second Quarter 2017 Financial Results](#)
- Aug 3, 2017*
[Cara Therapeutics to Webcast Presentation at the Canaccord Genuity 37th Annual Growth Conference](#)
- Aug 1, 2017*
[Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer](#)
- Jul 27, 2017*
[Cara Therapeutics to Announce Second Quarter 2017 Financial Results on August 3, 2017](#)
- Jul 12, 2017*
[Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease](#)

Financials [\[View all \]](#)

- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- May 10, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016*
[Quarterly Report \(10-Q\)](#)